JACOBSON PHARMA (02633): ULFERTS Pharmaceuticals enters into a licensing agreement with Li Zhongsheng Hall for 2025.
Jacobson Pharmaceuticals (02633) and Health Biotech (02161) jointly announced on February 28, 2025...
Jacobson Pharma (02633) and JBM Healthcare (02161) jointly announced that on February 28, 2025, Ulferts Pharmaceuticals and Lee Chung Sang Tong entered into a licensing agreement for the year 2025. Under this agreement, Ulferts Pharmaceuticals agreed to license Lee Chung Sang Tong to use part of the factory in accordance with the terms and conditions of the 2025 licensing agreement. The agreement is valid from January 28, 2025 to January 27, 2028 (including the first and last day), with a monthly license fee of HK$218,000.
Mr. Samson Sum, a non-executive director, chairman, and controlling shareholder of JBM Healthcare, holds approximately 59.92% equity in Jacobson Pharma. Ulferts Pharmaceuticals is an indirect wholly-owned subsidiary of Jacobson Pharma. Therefore, Ulferts Pharmaceuticals is the contact person for Mr. Samson Sum and the associate of JBM Healthcare.
Related Articles

HK Stock Market Move | Afternoon rise in oil stocks, the three oil giants continue to strengthen reserves and production, institutions say long-term investment value is highlighted.

HK Stock Market Move | MINIEYE (02431) rose more than 8% and won the Tongxiang unmanned vehicle project with a total amount of 11.85 million yuan.

Guotai Junan International: CHINA TRAVEL HK(03808) future performance is expected to continue to improve. Recommended to pay attention to the development of follow-up business.
HK Stock Market Move | Afternoon rise in oil stocks, the three oil giants continue to strengthen reserves and production, institutions say long-term investment value is highlighted.

HK Stock Market Move | MINIEYE (02431) rose more than 8% and won the Tongxiang unmanned vehicle project with a total amount of 11.85 million yuan.

Guotai Junan International: CHINA TRAVEL HK(03808) future performance is expected to continue to improve. Recommended to pay attention to the development of follow-up business.

RECOMMEND